The Canadian cannabis edibles market continues generating unprecedented traction and companies such as Indiva (TSXV:NDVA) remain poised to capitalize on this ever-growing industry.  

Case in point, it is anticipated that the Canadian cannabis market will reach C$7.2 billion in 2027 with most of that demand coming from provinces like Ontario, British Columbia and Alberta. 

Indiva, which is the leading Canadian-based producer of cannabis edibles, holds the top ranking in market share of sales and units sold in the edibles category across the provinces of B.C., with a 31.5 per cent share, as well as Alberta and Ontario with a 27.6 per cent share each.  

With the first quarter of the year well over and the second quarter of the year in full swing, the company recently announced its Q1 2024 financial results, highlighting some significant takeaways year-to-date thus far. 

Indiva reports Q1 2024 results 

In a press release, Indiva reported that its gross revenue for the quarter totalled C$10.6 million, which is a 15.2 per cent decrease from Q4 2023 and a 2.6 per cent increase year-over-year compared with Q1 2023. 

Niel Marotta, CEO of Indiva, told The Market Online that gross profit increased 18 per cent year-over-year and said the company’s profitability continues to improve.  

Despite Indiva’s revenue remaining flat in the quarter, Marotta explained that the company has transformed the business “significantly” over a 12-month period.  

“Over half of our revenue has basically been replaced,” he said, explaining that the company lost a product based on a regulation change, but that Indiva has been able to more than replace that loss with incremental revnue from some new brands.  

Other highlights from the company’s Q1 2024 financial results include:  

  • Net revenue from edible products was $8.4 million in Q1 2024, or 89.7 per cent of net revenue, up 14.7 per cent from $7.3 million in the prior year period, driven by strength in core brands including Pearls by Grön, No Future and Blips, offset by weakness in Wana. 
  • Gross profit increased 18.4 per cent to $2.8 million or 29.7 per cent of net revenue compared to $2.3 million or 24.8 per cent of net revenue in Q1 2023 due to lower impairments of inventory and positive mix impact. 
  • The company sold in Q1 2024 products containing 186 million milligrams of cannabinoids, the active ingredient in its products, which represents a 14.7 per cent decrease when compared to the 218 million milligrams in product sold in Q4 2024 

In terms of the company’s growth over the quarter, much of the company’s success came from its core brands such as Pearls by Grön gummies where depletions in three provinces more than doubled year-over-year.  

Indiva has also seen the continued growth of its No Future and Blips brands while more than 30 per cent of its net revenue in Q1 2024 came from Indiva-created-and-owned brands such as Indiva 1432 Chocolate, Indiva Blips tablets, Indiva Doppio Sandwich Cookies and No Future Gummies and Vapes. 

Q2 2024 and beyond outlook 

With Q2 in full swing, Indiva remains positive on its future outlook for the rest of the year and beyond, having already reached significant milestones in Q2 2024 alone. 

According to Marotta, April was the company’s “best month ever,” having pulled in more than $4 million in net revenue as well as generating positive net income. 

“[The company is] very happy with how Q2 is progressing and, in fact, with April and May together we’re already ahead of the revenue reported for the full Q2 last year,” he said.  

Essentially what this means is that Indiva is on track for sequential and year-over-year growth, which also includes the company expecting to report record revenue and record profitability by the end of the year.  

Investor’s corner 

As Canada’s largest market share holder in the edibles market, Indiva presents itself as a unique opportunity for investors looking for a low-cost option with massive potential upside. 

Thanks to its most successful month in terms of revenue in April and the expectation that it will report record revenue throughout the year, there’s no better time than now for investors to take the plunge with Indiva. 

Join the discussion: Find out what everybody’s saying about this stock on the Indiva Ltd. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards

This is sponsored content issued on behalf of Indiva please see the full disclaimer here.


More From The Market Online
Quantum computer

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal

Cybersecurity stock Quantum eMotion (TSXV:QNC) takes a major step in the go-to-market strategy for its Sentry-Q platform.
An AI generated photo of a stethoscope on a computerized setting

How one company is disrupting PoC testing

When it comes to Gemina Laboratories Ltd. (CSE:GLAB), the Canada and U.K.-based company is progressing a range of PoC diagnostic technologies.
AI generated stock image

Investing in Canadian medical stocks under $10

Healthcare stocks in Canada are publicly traded companies that operate in various sectors of the healthcare industry.
Bear and bull statues wearing Christmas hats

@ the Bell: TSX advances to start off Christmas trading week

Canada’s TSX index closed higher on Monday thanks to large-cap gains, despite weakness in real estate and telecom stocks.